Pricing Log in Create free account

CytomX Therapeutics, Inc. (CTMX) vs Monopar Therapeutics Inc. (MNPR)

CytomX Therapeutics, Inc. and Monopar Therapeutics Inc. are both Biotechnology companies. CytomX Therapeutics, Inc. and Monopar Therapeutics Inc. are of similar size ($466.3M and $451.2M). Monopar Therapeutics Inc. has the higher net margin (0.00% vs −630.4%) and the higher return on invested capital (0.00% vs −20.8%). Across the 12 metrics below, Monopar Therapeutics Inc. leads on 10 and CytomX Therapeutics, Inc. on 2.

Valuation

Metric CTMX MNPR Biotechnology median
P/E n/m n/m 10.60
P/S 34.21 n/m 9.40
P/B 1.68 4.66 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA n/m n/m 0.66
EV/Sales 10.89 n/m 9.02
Earnings yield (22.83%) (3.04%) (32.88%)
Free cash flow yield (10.61%) (2.00%) (23.13%)

Profitability

Metric CTMX MNPR Biotechnology median
Gross margin 100.00% — 68.51%
Operating margin (676.45%) 0.00% 0.00%
Net margin (630.38%) 0.00% 0.00%
Free cash flow margin (362.89%) 0.00% 0.00%
Return on equity (45.08%) (19.50%) (51.96%)
Return on assets (33.82%) (18.90%) (46.06%)
Return on invested capital (20.82%) 0.00% 0.00%

Growth

Metric CTMX MNPR Biotechnology median
Revenue growth (TTM) (87.66%) — 6.76%
EPS growth (last fiscal year) (139.47%) 54.99% 29.88%
Revenue growth, 5-year CAGR (5.36%) — 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric CTMX MNPR Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 7.82 33.56 4.97
Net debt to EBITDA 5.91 8.06 1.01

Dividend

Metric CTMX MNPR Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric CTMX MNPR Biotechnology median
Market cap 466.30m 451.19m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack